Core Insights - The eighth China International Import Expo (CIIE) has commenced in Shanghai, showcasing multinational medical device companies accelerating their localization efforts in China [2][3] - Boston Scientific has exhibited four unreleased products at the expo, all set to be produced at its Shanghai Lingang factory, marking a significant step in its localization journey [3][5] Localization Strategy - Boston Scientific's localization journey has progressed through three stages: from being an importer, to outsourcing production to local firms, and now establishing its own manufacturing facility in China [5][7] - The company has leveraged the Medical Device Registration Holder (MAH) system to facilitate local production, with the Polaris intravascular ultrasound system being a key milestone in this process [5][6] Recent Developments - In 2023, Boston Scientific made a strategic investment in Chinese medical device company Xianruida, enhancing its integration into the local supply chain and expanding its market reach [6][10] - The new factory in Lingang is designed to meet high standards and aims to become a leading smart factory for Boston Scientific globally, with plans for future expansion [6][7] Product Launches - By October 2024, the Lingang factory is expected to be operational, with four innovative products already in the pipeline for production, including the OptiCross/OptiCross HD catheter [9][12] - The AVVIGO+ intravascular ultrasound system, a complex machine developed with significant input from the Chinese team, is set to be one of the first products to be produced locally [12][14] Market Potential - The Chinese market is viewed as highly attractive due to its vast patient demand and the advantages of a local supply chain, which enhances efficiency and innovation [10][15] - Boston Scientific aims to better serve local markets and meet patient needs through its ongoing localization efforts, which are seen as a driving force for the company's growth in China [15]

Core Viewpoint - Boston Scientific is significantly expanding its localization strategy in China, leveraging the China International Import Expo (CIIE) to showcase innovative products and establish a strong foothold in the local market [2][3]. Group 1: Localization Strategy - Boston Scientific has achieved a "triple jump" in localization over six years, transitioning from an importer to a local manufacturer with its own factory in Shanghai [3][5]. - The company has successfully utilized the Medical Device Registration Holder (MAH) system to facilitate local production, exemplified by the Polaris intravascular ultrasound system, which received its first domestic registration certificate in July 2022 [6][7]. - In 2023, Boston Scientific made a strategic investment in the Chinese medical device company Xianruida, enhancing its integration into the local supply chain and expanding its product offerings [7][8]. Group 2: Product Development and Innovation - At the 2023 CIIE, Boston Scientific showcased four unreleased products, all set to be manufactured at its Shanghai factory, marking a significant step in its localization efforts [3][10]. - The AVVIGO+ intravascular ultrasound diagnostic system, a complex product developed with significant input from the Chinese team, demonstrates the company's commitment to local innovation [14][16]. - The Shanghai Lingang factory is designed to meet both Chinese and international standards, aiming to become a leading smart factory for Boston Scientific globally [7][8]. Group 3: Market Potential and Collaboration - The Chinese market is viewed as one of the most attractive and promising markets for Boston Scientific, driven by local supply chain advantages and increasing R&D capabilities [12][16]. - The company is actively engaging with local partners and government bodies to explore collaborative opportunities and enhance the local medical industry [15][17]. - Boston Scientific aims to better serve local patients by continuously introducing products and accelerating its localization process [17].

Core Insights - The China International Import Expo (CIIE) has evolved beyond its six-day event, creating a lasting "spillover effect" that connects global markets with China, enhancing trade and investment opportunities [1][3]. Group 1: Event Impact and Functionality - The CIIE has attracted global attention due to its unique positioning, large scale, diverse exhibits, and advanced technologies, leading to widespread acclaim from exhibitors and buyers [3]. - The "Hongqiao Pinhui" platform serves as a year-round exhibition and trading venue, having introduced over 6,000 brands from 108 countries, with a projected transaction volume of 28 billion RMB by 2024 [3]. - The platform has expanded to 48 centers across 22 cities by October 2025, facilitating cross-regional circulation of products [3]. Group 2: City Integration and Activities - The city of Shanghai has embraced the CIIE, with dedicated public transport routes and numerous promotional activities enhancing the event's visibility and engagement [4]. - Attendees can access various cultural and tourism discounts, promoting a deeper connection between the expo and the local economy [4]. Group 3: Policy Innovations - Shanghai has introduced the "CIIE Spillover Linkage Policy Package" to enhance convenience and attractiveness, focusing on customs, taxation, finance, and data cross-border flow [5]. - The "immediate tax refund" policy allows foreign buyers to process tax refunds on-site, significantly improving the shopping experience [5]. - A pilot program for data cross-border flow has been initiated, allowing exhibitors to send non-sensitive consumer data back to headquarters, which is seen as a significant breakthrough by multinational companies [5]. Group 4: Transformation of Exhibitors - The CIIE has facilitated the transformation of exhibits into marketable products, with 290 Fortune 500 companies participating, and 85 establishing regional headquarters or R&D centers in Shanghai [6]. - Boston Scientific has successfully launched 22 products in the Chinese market through the CIIE, showcasing its technological leadership [6]. - Samyang Foods has invested $140 million in a production base in Jiaxing, China, to meet the growing demand, with plans to produce 800 to 1,000 million servings of its popular spicy noodles annually [13]. Group 5: Comprehensive Platform for Cooperation - The CIIE has evolved into a comprehensive platform for international procurement, investment promotion, and cultural exchange, facilitating rich opportunities for collaboration [18]. - The event serves as a testing ground for institutional openness and regional cooperation, allowing global businesses to share in China's development [18].